ClinicalTrials.gg
CompletedNCT01959230Updated Oct 23, 2019Results posted

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

A Phase 3 interventional study of Brimonidine Tartrate and Vehicle in Hyperemia, sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-23.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Hyperemia with a site in United States — 9 open to participants now, 9 under way, 2 of them phase 3. Hyperemia · United States.

Enrollment
11th of 19
60 · median 68
Started
2013
the only one that year
Phase 3
6 of 23
2 open now
Registered
3rd of 23
by date
Lead sponsor
3 of 23
Bausch & Lomb Incorporated

Among the 23 studies in Hyperemia with a site in United States, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2013, is one of 6 in phase 3, and was the 3rd registered.

Hyperemia

98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.

Browse Hyperemia studies →

Open to participants now

9 of the 23 studies in Hyperemia with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Hyperemia studies recruiting now, 17 (61%) set no upper age limit and 7 (25%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hyperemia with a site in United States, or all of them as a file.
02

Study summary

To compare the efficacy and safety of brimonidine tartrate ophthalmic solution 0.025% with its vehicle for the treatment of ocular redness in a population of adult and geriatric participants with ocular redness.

03

Conditions studied

  • Hyperemia

Browse trials for

Keywords

  • Ocular redness
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age.
  • Have a history of redness relief drops use or expressed a desire to use drops for redness relief, within the last 6 months.
  • Have ocular health within normal limits including a calculated best-corrected visual acuity of 0.3 logarithm of the minimum angle of resolution (logMAR) or better in each eye, as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart.

Exclusion criteria

Exclusion Criteria:

  • Any ocular/systemic health problems.
  • Use of any disallowed medications.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Brimonidine Tartrate

    Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.

    Drug: Brimonidine Tartrate · Drug: Sodium Fluorescein · Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP

  • Placebo comparator
    Brimonidine Tartrate Vehicle

    Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.

    Drug: Vehicle · Drug: Sodium Fluorescein · Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP

Interventions

  • Ophthalmic solution to be applied as directed.

  • DrugVehicle

    Ophthalmic solution to be applied as directed.

  • DrugSodium Fluorescein

    For use as needed during the study for evaluating corneal damage.

  • DrugFluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP

    For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.

06

What researchers measure

Primary outcomes

  1. Ocular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia Scale

    Ocular redness using the Ora Calibra Ocular Hyperemia Scale was scored by the Investigator using the following scale (allowing half unit increments): 0=None; 1.0=Mild-Slightly dilated blood vessels, color of vessels is typically pink, can be quadrantal; 2.0=Moderate-More apparent dilation of blood vessels, vessel color is more intense (redder), involves the majority of the vessel bed; 3.0=Severe-Numerous and obvious dilated blood vessels, in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4.0=Extremely Severe-Large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed. A lower score is indicative of less redness.

    Time frame: 0 (predose), 5, 15, 30, 60, 90, 120, 180, and 240 minutes postdose on Day 1

Secondary outcomes

  1. Ocular Redness as Measured by the Participant

    Ocular redness was scored daily pre-dose and post-dose on Days 1 to 29 and scored daily on Days 30 to 36 by the participant using a 0 to 4 unit scale (not allowing half unit increments). A lower score was indicative of less redness. The LOCF method used for this Secondary Outcome Measure was for imputing missing daily post-dose mean scores for entire days. If ≥1 score was provided for a day, imputation was not done. Imputation was done within the dosing period and separately within the follow-up period. The average (mean) daily pre-dose and post-dose scores for the dosing period Day 1 to Day 15 and dosing period Day 15 to Day 29, and the average (mean) daily score for the follow-up period Day 29 to Day 36 are reported.

    Time frame: Day 1 to Day 15; Day 15 to Day 29; Day 29 to Day 36

  2. Change From Predose Ocular Redness Score as Measured by the Investigator Using the Ora Calibra Ocular Hyperemia Scale

    Ocular redness using the Ora Calibra Ocular Hyperemia Scale was scored by the Investigator using the following scale (allowing half unit increments): 0=None; 1.0=Mild-Slightly dilated blood vessels, color of vessels is typically pink, can be quadrantal; 2.0=Moderate-More apparent dilation of blood vessels, vessel color is more intense (redder), involves the majority of the vessel bed; 3.0=Severe-Numerous and obvious dilated blood vessels, in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4.0=Extremely Severe-Large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed. A lower score is indicative of less redness.

    Time frame: 0 (predose), 1, 360, and 480 minutes (min) postdose on Day 1 and 0 (predose), 1, and 5 min postdose on Days 15 and 29

07

Results

Posted Oct 23, 2019

Participant flow

Participant flow — Overall Study
MilestoneBrimonidine TartrateBrimonidine Tartrate Vehicle
Started4020
Received at least 1 dose of study drug4020
Completed3619
Not completed41
Withdrew: Failure to follow study procedures01
Withdrew: Administrative reasons20
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryOcular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia Scale

Ocular redness using the Ora Calibra Ocular Hyperemia Scale was scored by the Investigator using the following scale (allowing half unit increments): 0=None; 1.0=Mild-Slightly dilated blood vessels, color of vessels is typically pink, can be quadrantal; 2.0=Moderate-More apparent dilation of blood vessels, vessel color is more intense (redder), involves the majority of the vessel bed; 3.0=Severe-Numerous and obvious dilated blood vessels, in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4.0=Extremely Severe-Large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed. A lower score is indicative of less redness.

Time frame:
0 (predose), 5, 15, 30, 60, 90, 120, 180, and 240 minutes postdose on Day 1
Reported as:
Mean · units on a scale
Ocular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia Scale
units on a scaleBrimonidine TartrateBrimonidine Tartrate Vehicle
Predose1.82 ± 0.4121.71 ± 0.365
5 minutes Postdose0.58 ± 0.4971.40 ± 0.666
15 minutes Postdose0.58 ± 0.4971.35 ± 0.651
30 minutes Postdose0.59 ± 0.5111.40 ± 0.641
60 minutes Postdose0.61 ± 0.5091.40 ± 0.646
90 minutes Postdose0.60 ± 0.4761.45 ± 0.672
120 minutes Postdose0.63 ± 0.4701.53 ± 0.612
180 minutes Postdose0.73 ± 0.4491.54 ± 0.586
240 minutes Postdose0.82 ± 0.4741.54 ± 0.575
SecondaryOcular Redness as Measured by the Participant

Ocular redness was scored daily pre-dose and post-dose on Days 1 to 29 and scored daily on Days 30 to 36 by the participant using a 0 to 4 unit scale (not allowing half unit increments). A lower score was indicative of less redness. The LOCF method used for this Secondary Outcome Measure was for imputing missing daily post-dose mean scores for entire days. If ≥1 score was provided for a day, imputation was not done. Imputation was done within the dosing period and separately within the follow-up period. The average (mean) daily pre-dose and post-dose scores for the dosing period Day 1 to Day 15 and dosing period Day 15 to Day 29, and the average (mean) daily score for the follow-up period Day 29 to Day 36 are reported.

Time frame:
Day 1 to Day 15; Day 15 to Day 29; Day 29 to Day 36
Reported as:
Mean · units on a scale
Ocular Redness as Measured by the Participant
units on a scaleBrimonidine TartrateBrimonidine Tartrate Vehicle
Daily Predose Score of Day 1 to Day 151.52 ± 0.8571.83 ± 0.975
Daily Postdose Score of Day 1 to Day 150.85 ± 0.8601.85 ± 0.843
Daily Predose Score of Day 15 to Day 291.45 ± 0.8111.59 ± 1.012
Daily Postdose Score of Day 15 to Day 290.80 ± 0.8101.63 ± 0.887
Daily Score of Day 29 to Day 361.69 ± 0.8851.69 ± 0.897
SecondaryChange From Predose Ocular Redness Score as Measured by the Investigator Using the Ora Calibra Ocular Hyperemia Scale

Ocular redness using the Ora Calibra Ocular Hyperemia Scale was scored by the Investigator using the following scale (allowing half unit increments): 0=None; 1.0=Mild-Slightly dilated blood vessels, color of vessels is typically pink, can be quadrantal; 2.0=Moderate-More apparent dilation of blood vessels, vessel color is more intense (redder), involves the majority of the vessel bed; 3.0=Severe-Numerous and obvious dilated blood vessels, in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4.0=Extremely Severe-Large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed. A lower score is indicative of less redness.

Time frame:
0 (predose), 1, 360, and 480 minutes (min) postdose on Day 1 and 0 (predose), 1, and 5 min postdose on Days 15 and 29
Reported as:
Mean · units on a scale
Change From Predose Ocular Redness Score as Measured by the Investigator Using the Ora Calibra Ocular Hyperemia Scale
units on a scaleBrimonidine TartrateBrimonidine Tartrate Vehicle
Predose on Day 11.82 ± 0.4121.71 ± 0.365
Change from Predose at 1 min Postdose on Day 1-1.06 ± 0.625-0.23 ± 0.486
Change from Predose at 360 min Postdose on Day 1-0.78 ± 0.517-0.10 ± 0.440
Change from Predose at 480 min Postdose on Day 1-0.63 ± 0.570-0.13 ± 0.459
Predose on Day 151.57 ± 0.6451.24 ± 0.349
Change from Predose at 1 min Postdose on Day 15-0.78 ± 0.496-0.16 ± 0.279
Change from Predose at 5 min Postdose on Day 15-1.03 ± 0.569-0.25 ± 0.354
Predose on Day 291.64 ± 0.4611.36 ± 0.304
Change from Predose at 1 min Postdose on Day 29-0.88 ± 0.469-0.24 ± 0.306
Change from Predose at 5 min Postdose on Day 29-1.21 ± 0.416-0.37 ± 0.347

Adverse events

Collected over Baseline up to Day 36. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brimonidine Tartrate—0/40 (0%)10/40 (25%)
Brimonidine Tartrate Vehicle—0/20 (0%)1/20 (5%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventBrimonidine TartrateBrimonidine Tartrate Vehicle
Nasal congestionRespiratory, thoracic and mediastinal disorders0/401/20
BronchitisInfections and infestations1/400/20
Foreign body sensation in eyesEye disorders1/400/20
Lacrimation increasedEye disorders1/400/20
Abdominal discomfortGastrointestinal disorders1/400/20
Eye pruritusEye disorders1/400/20
Temporomandibular joint syndromeMusculoskeletal and connective tissue disorders1/400/20
PainGeneral disorders1/400/20
Muscle strainInjury, poisoning and procedural complications1/400/20
NasopharyngitisInfections and infestations1/400/20

Baseline characteristics

All randomized participants who received at least 1 dose of study drug (Safety Population).

Age, Continuous
Age, Continuous(years)Brimonidine TartrateBrimonidine Tartrate VehicleTotal
Mean47.6 ± 15.3747.4 ± 15.3647.5 ± 15.24
Sex: Female, Male
Sex: Female, Male(Participants)Brimonidine TartrateBrimonidine Tartrate VehicleTotal
Female221638
Male18422
08

Study locations

1 site
  • Bausch & Lomb Incorporated
    Memphis, Tennessee 38119, United States
09

References and documents

Publications

  • McLaurin E, Cavet ME, Gomes PJ, Ciolino JB. Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial. Optom Vis Sci. 2018 Mar;95(3):264-271. doi: 10.1097/OPX.0000000000001182. PubMed 29461408 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2013 to primary completion in Dec 2013, 1 month.

Results were first posted in Oct 2019, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2013
First posted
Oct 9, 2013
StartActual
Nov 7, 2013
Primary completionActual
Dec 20, 2013
CompletionActual
Dec 20, 2013
Results first posted
Oct 23, 2019
Last update
Oct 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01959230
Collaborators
ORA, Inc.
Responsible party
Sponsor
First posted
Oct 9, 2013
Start date
Nov 7, 2013
Primary completion
Dec 20, 2013
Completion
Dec 20, 2013
Results posted
Oct 23, 2019
Last update
Oct 23, 2019

Study contacts

Heleen DeCory
study director · Bausch & Lomb Incorporated

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion